Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate

E. Laukhtina, M. Moschini, W. Krajewski, JY. Teoh, G. Ploussard, F. Soria, F. Roghmann, MA. Muenker, M. Roumiguie, M. Alvarez-Maestro, V. Misrai, A. Antonelli, A. Tafuri, G. Simone, R. Mastroianni, H. Zhao, RG. Rahota, D. D'Andrea, K. Mori, S....

. 2023 ; 131 (5) : 571-580. [pub] 20221003

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23011661

OBJECTIVES: To determine the oncological impact and adverse events of performing simultaneous transurethral resection of bladder tumour (TURB) and transurethral resection of the prostate (TURP), as evidence on the outcomes of simultaneous TURB for bladder cancer and TURP for obstructive benign prostatic hyperplasia is limited and contradictory. PATIENTS AND METHODS: Patients from 12 European hospitals treated with either TURB alone or simultaneous TURB and TURP (TURB+TURP) were retrospectively analysed. A propensity score matching (PSM) 1:1 was performed with patients from the TURB+TURP group matched to TURB-alone patients. Associations between surgery approach with recurrence-free (RFS) and progression-free (PFS) survivals were assessed in Cox regression models before and after PSM. We performed a subgroup analysis in patients with risk factors for recurrence (multifocality and/or tumour size >3 cm). RESULTS: A total of 762 men were included, among whom, 76% (581) underwent a TURB alone and 24% (181) a TURB+TURP. There was no difference in terms of tumour characteristics between the groups. We observed comparable length of stay as well as complication rates including major complications (Clavien-Dindo Grade ≥III) for the TURB-alone vs TURB+TURP groups, while the latest led to longer operative time (P < 0.001). During a median follow-up of 44 months, there were more recurrences in the TURB-alone (47%) compared to the TURB+TURP group (28%; P < 0.001). Interestingly, there were more recurrences at the bladder neck/prostatic fossa in the TURB-alone group (55% vs 3%, P < 0.001). TURB+TURP procedures were associated with improved RFS (hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.29-0.53; P < 0.001), but not PFS (HR 1.63, 95% CI 0.90-2.98; P = 0.11). Within the PSM cohort of 254 patients, the simultaneous TURB+TURP was still associated with improved RFS (HR 0.33, 95% CI 0.22-0.49; P < 0.001). This was also true in the subgroup of 380 patients with recurrence risk factors (HR 0.41, 95% CI 0.28-0.62; P < 0.001). CONCLUSION: In our contemporary cohort, simultaneous TURB and TURP seems to be an oncologically safe option that may, even, improve RFS by potentially preventing disease recurrence at the bladder neck and in the prostatic fossa.

Cancer Prognostics and Health Outcomes Unit University of Montreal Health Centre Montreal Canada

Departement of Urology University of Verona Verona Italy

Department of Minimally Invasive and Robotic Urology University Center of Excellence in Urology Wrocław Medical University Wroclaw Poland

Department of Surgery Prince of Wales Hospital The Chinese University of Hong Kong Hong Kong China

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Clinique Pasteur Toulouse France

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology La Croix du Sud Hospital Institut Universitaire du Cancer Toulouse Oncopole Toulouse France

Department of Urology Marien Hospital Herne Herne Germany

Department of Urology The Jikei University School of Medicine Tokyo Japan

Department of Urology University Hospital of Toulouse Rangueil Toulouse France

Department of Urology University of Texas Southwestern Dallas TX USA

Department of Urology Weill Cornell Medical College New York NY USA

Division of Experimental Oncology Unit of Urology Urological Research Institute Milan Italy

Division of Urology Department of Surgical Sciences AOU Città della Salute e della Scienza di Torino Torino School of Medicine Turin Italy

Hourani Center for Applied Scientific Research Al Ahliyya Amman University Amman Jordan

IRCCS Regina Elena National Cancer Institute Rome Italy

Karl Landsteiner Institute of Urology and Andrology Vienna Austria

Service d'Urologie Hôpital Erasme Université Libre de Bruxelles Brussels Belgium

Servicio de Urología Hospital Universitario La Paz Madrid Spain

University Vita Salute San Raffaele Milan Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011661
003      
CZ-PrNML
005      
20230801133232.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bju.15898 $2 doi
035    __
$a (PubMed)36134575
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000289530272
245    10
$a Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate / $c E. Laukhtina, M. Moschini, W. Krajewski, JY. Teoh, G. Ploussard, F. Soria, F. Roghmann, MA. Muenker, M. Roumiguie, M. Alvarez-Maestro, V. Misrai, A. Antonelli, A. Tafuri, G. Simone, R. Mastroianni, H. Zhao, RG. Rahota, D. D'Andrea, K. Mori, S. Albisinni, PI. Karakiewicz, H. Fajkovic, D. Enikeev, F. Montorsi, SF. Shariat, B. Pradere, European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group
520    9_
$a OBJECTIVES: To determine the oncological impact and adverse events of performing simultaneous transurethral resection of bladder tumour (TURB) and transurethral resection of the prostate (TURP), as evidence on the outcomes of simultaneous TURB for bladder cancer and TURP for obstructive benign prostatic hyperplasia is limited and contradictory. PATIENTS AND METHODS: Patients from 12 European hospitals treated with either TURB alone or simultaneous TURB and TURP (TURB+TURP) were retrospectively analysed. A propensity score matching (PSM) 1:1 was performed with patients from the TURB+TURP group matched to TURB-alone patients. Associations between surgery approach with recurrence-free (RFS) and progression-free (PFS) survivals were assessed in Cox regression models before and after PSM. We performed a subgroup analysis in patients with risk factors for recurrence (multifocality and/or tumour size >3 cm). RESULTS: A total of 762 men were included, among whom, 76% (581) underwent a TURB alone and 24% (181) a TURB+TURP. There was no difference in terms of tumour characteristics between the groups. We observed comparable length of stay as well as complication rates including major complications (Clavien-Dindo Grade ≥III) for the TURB-alone vs TURB+TURP groups, while the latest led to longer operative time (P < 0.001). During a median follow-up of 44 months, there were more recurrences in the TURB-alone (47%) compared to the TURB+TURP group (28%; P < 0.001). Interestingly, there were more recurrences at the bladder neck/prostatic fossa in the TURB-alone group (55% vs 3%, P < 0.001). TURB+TURP procedures were associated with improved RFS (hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.29-0.53; P < 0.001), but not PFS (HR 1.63, 95% CI 0.90-2.98; P = 0.11). Within the PSM cohort of 254 patients, the simultaneous TURB+TURP was still associated with improved RFS (HR 0.33, 95% CI 0.22-0.49; P < 0.001). This was also true in the subgroup of 380 patients with recurrence risk factors (HR 0.41, 95% CI 0.28-0.62; P < 0.001). CONCLUSION: In our contemporary cohort, simultaneous TURB and TURP seems to be an oncologically safe option that may, even, improve RFS by potentially preventing disease recurrence at the bladder neck and in the prostatic fossa.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    _2
$a prostata $x chirurgie $x patologie $7 D011467
650    12
$a transuretrální resekce prostaty $x škodlivé účinky $x metody $7 D020728
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a lokální recidiva nádoru $x patologie $7 D009364
650    12
$a hyperplazie prostaty $x komplikace $7 D011470
650    12
$a nádory močového měchýře $x patologie $7 D001749
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Moschini, Marco $u Division of Experimental Oncology/Unit of Urology, Urological Research Institute, Milan, Italy $1 https://orcid.org/0000000230842458
700    1_
$a Krajewski, Wojciech $u Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wrocław Medical University, Wroclaw, Poland $1 https://orcid.org/0000000317272283
700    1_
$a Teoh, Jeremy Yuen-Chun $u Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China $1 https://orcid.org/0000000293612342
700    1_
$a Ploussard, Guillaume $u Department of Urology, La Croix du Sud Hospital, Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France $1 https://orcid.org/0000000260042152
700    1_
$a Soria, Francesco $u Division of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza di Torino, Torino School of Medicine, Turin, Italy $1 https://orcid.org/0000000184438453
700    1_
$a Roghmann, Florian $u Department of Urology, Marien Hospital Herne, Herne, Germany $1 https://orcid.org/000000030299489X
700    1_
$a Muenker, Mara Anna $u Department of Urology, Marien Hospital Herne, Herne, Germany
700    1_
$a Roumiguie, Mathieu $u Department of Urology, University Hospital of Toulouse Rangueil, Toulouse, France $1 https://orcid.org/000000022412146X
700    1_
$a Alvarez-Maestro, Mario $u Servicio de Urología, Hospital Universitario La Paz, Madrid, Spain $1 https://orcid.org/0000000307057643
700    1_
$a Misrai, Vincent $u Department of Urology, Clinique Pasteur, Toulouse, France $1 https://orcid.org/0000000320290650
700    1_
$a Antonelli, Alessandro $u Departement of Urology, University of Verona, Verona, Italy $1 https://orcid.org/0000000274558803
700    1_
$a Tafuri, Alessandro $u Departement of Urology, University of Verona, Verona, Italy $1 https://orcid.org/0000000314042925
700    1_
$a Simone, Giuseppe $u IRCCS "Regina Elena" National Cancer Institute, Rome, Italy $1 https://orcid.org/0000000248689025
700    1_
$a Mastroianni, Riccardo $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/0000000337082209
700    1_
$a Zhao, Hongda $u Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China $1 https://orcid.org/0000000324141484
700    1_
$a Rahota, Razvan-George $u Department of Urology, La Croix du Sud Hospital, Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France $1 https://orcid.org/0000000328752936
700    1_
$a D'Andrea, David $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000316251077
700    1_
$a Mori, Keiichiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/0000000261476569
700    1_
$a Albisinni, Simone $u Service d'Urologie, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium $1 https://orcid.org/0000000155293064
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada
700    1_
$a Fajkovic, Harun $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $1 https://orcid.org/0000000197649962
700    1_
$a Enikeev, Dmitry $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000171692209
700    1_
$a Montorsi, Francesco $u Division of Experimental Oncology/Unit of Urology, Urological Research Institute, Milan, Italy $u University Vita-Salute San Raffaele, Milan, Italy $1 https://orcid.org/0000000272674181
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan $1 https://orcid.org/0000000266276179
700    1_
$a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, La Croix du Sud Hospital, Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France $1 https://orcid.org/0000000277688558
710    2_
$a European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group
773    0_
$w MED00011371 $t BJU international $x 1464-410X $g Roč. 131, č. 5 (2023), s. 571-580
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36134575 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801133228 $b ABA008
999    __
$a ok $b bmc $g 1963856 $s 1197926
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 131 $c 5 $d 571-580 $e 20221003 $i 1464-410X $m BJU international $n BJU Int $x MED00011371
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...